Forza Wealth Management LLC Acquires 5,500 Shares of Sanofi (NASDAQ:SNY)

Forza Wealth Management LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 147.3% in the fourth quarter, Holdings Channel reports. The firm owned 9,235 shares of the company’s stock after purchasing an additional 5,500 shares during the quarter. Forza Wealth Management LLC’s holdings in Sanofi were worth $445,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC lifted its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after buying an additional 3,164,092 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after acquiring an additional 246,224 shares during the period. Natixis Advisors LLC boosted its stake in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after purchasing an additional 114,133 shares in the last quarter. Finally, Raymond James & Associates grew its holdings in shares of Sanofi by 4.8% in the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after purchasing an additional 129,472 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 0.3 %

NASDAQ:SNY traded down $0.17 during trading hours on Monday, hitting $48.56. 1,534,291 shares of the stock were exchanged, compared to its average volume of 2,243,400. The company’s 50 day moving average is $48.70 and its two-hundred day moving average is $52.11. The company has a market capitalization of $123.24 billion, a P/E ratio of 24.78, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.55 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNY has been the topic of a number of recent analyst reports. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.